Biocon Ltd: Block Deal Removes Overhang; Earnings to Drive Next Move

Biocon witnessed a strong rally after Mylan Inc., a subsidiary of Viatris, exited its entire 5.64% stake through a block deal worth over ₹3,500 crore. While the identities of the institutional buyers are yet to be officially disclosed, the successful absorption of such a large stake has boosted investor confidence. The market viewed the completion of Mylan's exit as a positive development, removing a long-standing supply overhang and improving sentiment toward the stock. Technically, Biocon has delivered a decisive breakout with strong volumes and continues to trade within a rising channel, indicating sustained medium-term strength. The stock is comfortably above its 20, 50, 100 and 200-day moving averages, highlighting a healthy bullish trend. RSI is hovering around 62, suggesting positive momentum without entering the overbought zone, while expanding Bollinger Bands indicate increasing volatility and the potential for further upside. Immediate support is placed in the ₹420-416 zone, followed by a stronger support near ₹400. On the upside, the stock is approaching the upper boundary of its rising channel around ₹445-450. A decisive close above ₹445 could open the door for ₹460 initially, with the possibility of extending towards ₹475-490 over the next 6-8 weeks. The next major trigger will be Biocon's Q1 FY27 earnings, expected in the first week of August. Investors will closely monitor biosimilars and generics performance, margin expansion, product pipeline updates and management's outlook. A strong earnings performance, coupled with the removal of the Mylan stake-sale overhang, could provide fresh momentum for the stock. Overall, the technical and sentiment indicators remain favourable, making Biocon an attractive stock to watch for positional investors.